Philips Agrees to Acquire SpectraWave

December 15, 2025—Royal Philips announced it has entered into an agreement to acquire SpectraWave, Inc.

Founded in 2017 and based in Bedford, Massachusetts, SpectraWave is a developer of technology for enhanced vascular imaging (EVI) of coronary arteries, angiography-based physiology assessments, and the use of artificial intelligence (AI) in medical imaging. Its intravascular imaging and physiologic assessment technologies provide solutions for the treatment of patients with coronary artery disease, noted the press release.

According to Philips, SpectraWave’s HyperVue imaging system is an intravascular imaging platform that combines next-generation comprehensive optical coherence tomography—DeepOCT—and near-infrared spectroscopy (NIRS) into its EVI imaging segment to provide detailed structural and compositional images of the coronary arteries during percutaneous coronary interventions with rapid setup, acquisition, and automated AI image analysis.

Combined with Philips’ Eagle Eye Platinum digital intravascular ultrasound (IVUS) and IntraSight technologies, HyperVue will expand clinicians’ intravascular imaging toolbox—IVUS, DeepOCT, NIRS, and wire and angio-derived physiology—all orchestrated through integrated systems to tailor guidance to each patient and lesion, noted Philips.

Additionally, the press release advised that SpectraWave offers an angiography-derived, AI-enabled physiology solution that calculates fractional flow reserve (FFR) from a single coronary angiogram. The solution, X1-FFR, provides a noninvasive ischemia assessment, turning routine X-ray images into coronary physiology data for simplified percutaneous coronary intervention workflows.

X1-FFR complements Philips’ OmniWire instantaneous wave-free ratio (iFR) technology by extending physiologic guidance to wire-free scenarios and equipping clinicians with a versatile toolkit to broaden the adoption of coronary physiology in daily practice, stated Philips.